Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*
Authors:
- 24 November 2011
- journal article
- practice guideline
- Published by Wiley in British Journal of Haematology
- Vol. 156 (2) , 186-195
Abstract
Summary: The British Committee for Standards in Haematology first produced guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant in 2000. This revision updates those guidelines and covers the areas of diagnosis, treatment and assessment of response to therapy.Keywords
This publication has 47 references indexed in Scilit:
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- How I treat hairy cell leukemiaBlood, 2010
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2009
- Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisBritish Journal of Haematology, 2009
- Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow‐upBritish Journal of Haematology, 2008
- The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemiaCancer, 2007
- Eradication of minimal residual disease in hairy cell leukemiaBlood, 2006
- Rituximab as treatment for minimal residual disease in hairy cell leukaemiaEuropean Journal of Haematology, 2004
- An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosineLeukemia, 2004
- Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsLeukemia, 2003